Search
Prelude Therapeutics Inc
PRLDAdd to Watchlist
4.910USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
309.10MMarket Cap
LossP/E TTM
More Details of Prelude Therapeutics Inc Company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Prelude Therapeutics Inc Info
Ticker SymbolPRLD
Company namePrelude Therapeutics Inc
IPO dateSep 25, 2020
CEOVaddi (Krishna)
Number of employees131
Security typeOrdinary Share
Fiscal year-endSep 25
Address175 Innovation Boulevard
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19805
Phone13024671280
Websitehttps://preludetx.com/
Ticker SymbolPRLD
IPO dateSep 25, 2020
CEOVaddi (Krishna)
Company Executives of Prelude Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Prelude Therapeutics Inc?
The top five shareholders of Prelude Therapeutics Inc are: Dr. Krishna (Kris) Vaddi, Ph.D.
How many institutions hold shares of Prelude Therapeutics Inc (PRLD)?
As of 2026Q1, 149 institutions hold shares of Prelude Therapeutics Inc, with a combined market value of approximately 30.05M, accounting for 57.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7756404.00.